Heart failure (HF) imposes a large and growing burden on the population, with a prevalence that is projected to increase to more than 8 million adults by 2030. The high risk of morbidity and mortality ...
Credit: Getty Images. The approval was based on data from the phase 3 EMPEROR-Reduced trial. The Food and Drug Administration (FDA) has approved Jardiance ® (empagliflozin) to reduce the risk of ...
Patients with newly diagnosed heart failure with reduced ejection fraction (HFrEF) commonly have improvements in their LVEF, but that doesn’t mean they can let their guard down, data from a large ...
Results from the Phase 3 VICTOR trial and a pooled analysis of the VICTOR and VICTORIA trials were presented today at the ESC Congress 2025 and simultaneously published in The Lancet VERQUVO was ...
The therapeutic efficacy of the cardiac glycoside digitoxin in patients with heart failure and reduced ejection fraction is not established. In this international, double-blind, placebo-controlled ...
"These findings suggest that small variations in the amount of fluid given to a patient with sepsis, or the decision to give less fluid to a patient because they have heart failure, may not have a ...
Heart failure is a heterogeneous syndrome. Approximately 30–50% of patients with heart failure have normal or near normal left ventricle function. Several epidemiological studies confirm that the ...
A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results